University of Ioannina
Συγκριτική μελέτη της αντιαιμοπεταλιακής δράσης διαφορετικών αλάτων της κλοπιδογρέλης σε ασθενείς με καρδιαγγειακή νόσο
Abstract
dc:descriptionClopidogrel is a widely used antiplatelet drug for the secondary prevention of atherothrombotic events, in combination with aspirin or as monotherapy. Clopidogrel’ clinical benefit has been well established by a plethora of large clinical trials as well as in the real world clinical practice. All this knowledge and experience have been obtained by using the original product clopidogrel hydrogen sulphate (CHS; Plavix®/Iscover®). After expiration of its pharmaceutical patent in May 2012, clopidogrel has become generic thus several commercial salt formulations have been developed and approved for use worldwide including Europe and USA for the secondary prevention of atherothrombotic events. These include clopidogrel base, clopidogrel resinate, clopidogrel hydrochloride and clopidogrel besylate (CB). During the development of a new generic formulation, it is important to adhere to the manufacturing process and to use the same excipients as in the original salt in order to minimize stability problems. Specifically, during the development phase of an oral solid dosage form, several physiochemical as well as preformulation and formulation tests are carried out in order to achieve a highquality generic product that is interchangeable with the original brand in terms of efficacy and safety. Accordingly, a generic product must show a dissolution profile in vitro, similar or overlapping that of the original product,in order to ensure a successful bioequivalence profile of the product.However, according to the Biopharmaceutics Classification System, clopidogrel is a Class II product, thus in vitro dissolution is not sufficient to prove that it is interchangeable with the original brand. Thus, clopidogrel generic tablets should be subjected to bioequivalence study in comparison with the original formulation. Furthermore, it is of critical importance to demonstrate that these preparations have similar pharmacodynamic potency in inhibiting platelet reactivity and also are clinically bioequivalent to the original salt in terms of efficacy and safety. In this regard, it should be emphasized that in contrast with other generic cardiovascular medications, such as statins or antihypertensives, for which minor differences in their biologic efficacy would be unlikely to have any discernible clinical effect, aminor decrement in the clopidogrel pharmacodynamic potency could result in severe ischemic thrombotic complications, especially in situations where therapeutic efficacy is critical, such as immediately after a percutaneous coronary intervention. The necessity for evaluating the therapeutic efficacy of a generic clopidogrel salt is further supported by the substantial heterogeneity existing among various generic clopidogrel formulations, in terms of clopidogrel content, impurity profile, dissolution properties and stability,even if these concern the same salt. Today, a number of small and often under powered studies comparing either pharmacodynamic or clinical endpoints in patients receiving generic versus brand name clopidogrel have been conducted. Among them, very few studies used hard outcomes and followed patients for more than 3 months, while many trials were conducted in healthy volunteers. Our working group had published two studies which were concluded that there was pharmacodynamic bioequivalence between ageneric CB formulation with that of the original CHS in patients within 1 and 6-months of follow-up after acute coronary syndrome. AIM:The aim of the present study was to compare the clinical efficacy and safety of CB formulation with that of the original CHS, which were administered for 12-months in a relatively large number of patients eligible to receive clopidogrel according to the indications and the guidelines. The interim analysis of this trial was performed at 6-months of follow-up. METHODS:A prospective 2-arm, multi center, open-label, phase 4 clinical trial which was named “Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence(SCIENCE)” was performed. During this trial 1,864 consecutive patients were screened and 1,800 were enrolled in the trial and randomized to CHS or CB. Primary efficacy end point was the composite of myocardial infarction, stroke,or death from vascular causes, and primary safety end point was the rate of bleeding events as defined by Bleeding Academic Research Consortium(BARC) criteria. RESULTS: At 6-months follow-up no differences were observed between CB (n = 759)and CHS (n = 798) in primary efficacy end point (OR, 0.80; 95% CI, 0.37 to1.71; p=0.57). Rates of BARC-1,-2,-3a and -5b bleeding events were similar between the two study groups whereas no bleeding events according to BARC-3b, -3c, -4 and -5a were observed in either CHS or CB group.At 12-months follow-up, no differences were observed between CB and CHSin primary efficacy and safety end points (age, sex, history of percutaneous coronary intervention adjusted odds ratio [OR], 0.70; 95% confidence interval[CI], 0.41-1.21 and OR, 0.81; 95% CI, 0.51-1.29, respectively). Analyses of efficacy and safety in subgroups that were defined according to the qualifying diagnosis revealed that there was no difference between CHS and CB. CONCLUSION: The present clinical trial revealed that the clinical efficacy of CB salt administered for 12 months in several types of patients eligible to receive clopidogrel is similar to that of the innovator CHS salt. Furthermore, both clopidogrel formulations exhibited similar safety profile. The interim analysisof this trial which was performed at 6-months of follow-up also demonstrated that there were no differences in the clinical primary and secondary efficacy as well as safety end points between CB and CHS. To our knowledge this is the largest clinical trial performed to date in terms of population size, study duration and subgroups of patients, aiming to compare the efficacy and safety of a generic clopidogrel salt with the innovator drug in the secondary prevention of atherothrombotic events. (Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence, SCIENCE trial; ClinicalTrials. gov Identifier: NCT02126982). AKNOWLEDGEMENT OF GRANT SUPPORT: This study was partially funded by the European Union through the Operational Programme "Competitiveness and Entrepreneurship" of the National Strategic Reference Framework (NSRF)-Research Funding Programme: Cooperation 2009 Action I. Small and medium scale Cooperative(project code: 09SYN-12-827) and by the Audit Committee through the special account for research funds (ΕLKE) of the University of Ioannina. This studywas partially supported also by grants from ELPEN (Greece), manufacturer ofthe clopidogrel besylate formulation (Clovelen®) used in the present study.However, the sponsor had no involvement in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data or in the preparation, review, submission and approval of the published articles.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ntalas, Ioannis
- Ντάλας, Ιωάννης
Subjects
dc:subject × 22- Οξύ στεφανιαίο σύνδρομο
- Κλινική αποτελεσματικότητα
- Άλατα κλοπιδογρέλης
- Βεσθλική κλοπιδογρέλη
- Στεφανιαία νόσος
- Γενόσημα φάρμακα
- Περιφερική αρτηριακή νόσος
- Εγκεφαλικό επεισόδιο
- Acute coronary syndrome
- Clinical efficacy
- Salis of clopidogrel
- Clopidogrel besylate
- Coronary artery disease
- Qeneric drygs
- Peripheral artery disease
- Stroke
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44273